argenx (ARGX) Stock Forecast & Price Target

argenx is a promising investment with its recent FDA approvals for Vyvgart and Vyvgart Hytrulo for the treatment of rare autoimmune diseases. With a strong focus on innovation and developing its pipeline, the company has potential for future growth and expansion. While there are risks involved, including clinical and regulatory failures, argenx's experienced management team and established commercial footprint in other rare disease areas make it a favorable investment option.

argenx is a biopharmaceutical company with a promising pipeline targeting rare autoimmune diseases. The recent FDA approvals of Vyvgart and Vyvgart Hytrulo for myasthenia gravis (gMG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) demonstrate success in developing and commercializing innovative treatments. The company's focus on expanding into other autoimmune diseases, such as primary immune thrombocytopenia and thyroid eye disease, presents future growth potential. However, argenx's financial outlook remains uncertain, with minimal current revenues and a reliance on future drug sales.